1. Role: Dean. Scope: University. Description: Dean of the Graduate College. Responsible for Graduate Programs on the Health Sciences Campus and the Postdoctoral Office. Date: 2014.
H. Anne Pereira, Ph.D.
Dean, Graduate College and David L. Boren Professor
Pharmaceutical Sciences
Phone (405) 271-6593 x58034
Fax (405) 271-7505
Office CPB 329
Email anne-pereira@ouhsc.edu
Summary
My laboratory investigates the role of a novel inflammatory mediator known as CAP37. We focus on the significance of this protein in host defense against severe infections including infections of the eye and in various inflammatory mediated diseases such as atherosclerosis and Alzheimer's disease. We currently employ a combination of cellular, immunological, biochemical and molecular approaches at the in vitro and in vivo level to solve these questions. Our long-term goals are to design new and effective antibiotics and anti-inflammatory therapeutics.
Research
This laboratory investigates the role of a novel inflammatory mediator known as CAP37. We focus on the significance of this protein in host defense against severe infections including infections of the eye and in various inflammatory mediated diseases such as atherosclerosis and Alzheimer's disease. We currently employ a combination of cellular, immunological, biochemical and molecular approaches at the in vitro and in vivo level to solve these questions. Our long-term goals are to design new and effective antibiotics and anti-inflammatory therapeutics.
Patents
Biomarker and method for detecting a chronic inflammatory-associated disease
Patent No. 8,450,071
USA
H. Anne Pereira
Publications & Presentations
- 1. Kasus-Jacobi A, Washburn J L, Laurence R B, Pereira A. Selecting Multitarget Peptides for Alzheimer's Disease. Biomolecules. 2022; 12 : 1386
2. Kasus-Jacobi A, Washburn J, Land C, Pereira A. Neutrophil Granule Proteins Inhibit Amyloid Beta Aggregation and Neurotoxicity. Current Alzheimer Research. 2021; 18 : 414-427
3. Kasus-Jacobi A, Land C, Stock A, Washburn J, Pereira A. Antimicrobial peptides derived from the immune defense protein CAP37 inhibit TLR4 activation by S100A9. Investigative Ophthalmology & Visual Science/Association for Research in Vision and Ophthalmology. 2020
4. Stock A J, Kasus-Jacobi A, Pereira A. The role of neutrophil granule proteins in neuroinflammation and Alzheimer's disease. Journal of neuroinflammation. 2018; 15 : 240
5. Kasus-Jacobi A, Griffith G L, Lerner M, Pereira A. Effect of Cationic Antimicrobial Protein CAP37 on Cytokine Profile during Corneal Wound Healing. Journal of Ocular Diseases and Therapeutics. 2017; 5 : 19-27
Grants
- 1. Oklahoma Shared Clinical and Translational Resources. NIH. Start Date: 2023. End Date: 2028.
2. Vision Science Training Program. NIH. Start Date: 2021. End Date: 2026.
3. STTR Phase 1: Multi-target Peptide Drug for Alzheimer's Disease. NIA. Start Date: 2024. End Date: 2025.
4. STTR Phase 1: Novel Ophthalmic Product for Corneal Infections and Injuries. NIH. Start Date: 2021. End Date: 2023.
5. Oklahoma Shared Clinical and Translational Resources. NIH. Start Date: 2018. End Date: 2023.
Awards and Honors
- 11. The Journal Record. On the Brink, Award for Innovation. Date: 2006.
12. Department of Pathology. Fred G Silva Research Award. Date: 1999.
13. American Heart Association. Established Investigator. Date: 1998.
14. OUHSC. Provosts' Research Award to Junior Faculty. Date: 1994.
15. OUHSC. Faculty Leadership Program. Date: 1992.
Education
- 1. Degree: Ph D. University of Melbourne. Date: 1982.
2. Degree: BSc (Honours) First class honours & First Place. University of Melbourne. Date: 1976.
3. Degree: BS. University of Melbourne. Date: 1975.
Administrative Assignments
2. Role: Associate Dean. Scope: College. Description: Responsible for Oversight of research activities in the College of Pharmacy, mentoring junior faculty and trainees. Date: 2009.